Relay Therapeutics (RLAY)

• Market cap: $622M
• 1 day: 0.28%
• 5 days: -3.97%
• 1 month: 4.91%
• 3 months: 9.01%
• 6 months: -20.04%
• Year to date: -15.58%
• 1 year: -56.11%
• 5 years: -89.63%
• 10 years: -89.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Employees: 259

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

274% more call options, than puts

Call options by funds: $483K | Put options by funds: $129K

46% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 24

28% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 58

4% more funds holding

Funds holding: 199 [Q4 2024] → 207 (+8) [Q1 2025]

1.95% less ownership

Funds ownership: 97.95% [Q4 2024] → 96.0% (-1.95%) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]

37% less capital invested

Capital invested by funds: $676M [Q4 2024] → $427M (-$249M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 175% upside
• Avg. target: $10 175% upside
• High target: $10 175% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Michael Schmidt

175% upside $10

Buy Maintained

7 May 2025